Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

19.65 (USD) • At close September 13, 2024
Bedrijfsnaam Rocket Pharmaceuticals, Inc.
Symbool RCKT
Munteenheid USD
Prijs 19.65
Beurswaarde 1,787,676,435
Dividendpercentage 0%
52-weken bereik 16.55 - 32.525
Industrie Biotechnology
Sector Healthcare
CEO Dr. Gaurav D. Shah M.D.
Website https://rocketpharma.com

An error occurred while fetching data.

Over Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or

Vergelijkbare Aandelen

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.329 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

17.49 USD

Codexis, Inc. logo

Codexis, Inc.

CDXS

2.78 USD

Nektar Therapeutics logo

Nektar Therapeutics

NKTR

1.31 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

7.9 USD

uniQure N.V. logo

uniQure N.V.

QURE

5.66 USD

Merus N.V. logo

Merus N.V.

MRUS

50.14 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)